Dr. Reddy’s Launches ‘Obeda’ Semaglutide Injection in India, Enters High-Growth GLP-1 Diabetes Market
In a major step toward expanding its footprint in advanced diabetes care, Dr. Reddy’s Laboratories has announced the launch of its semaglutide-based injectable therapy, Obeda, in India. This move marks … Read More